Limits...
Burden of herpes zoster and post-herpetic neuralgia in Sweden.

Nilsson J, Cassel T, Lindquist L - BMC Infect. Dis. (2015)

Bottom Line: Medication was a relatively small contributor with 8.5 MSEK (4 %; 1.0 M€) to the overall costs for patients at all ages.The corresponding total cost including only patients 50 years and older was 168 MSEK (19.2 M€) or 8,200 SEK (€939) per patient.The society, the health care payers and the patients potentially have a lot to gain by introducing a vaccination program to patients 50 years and older and as a consequence reduce the economic and clinical burden of herpes zoster and post-herpetic neuralgia.

View Article: PubMed Central - PubMed

Affiliation: Mapi Group, Stockholm, Klarabergsviadukten 90D, SE-111 64, Stockholm, Sweden. Jonas.nilsson@optum.com.

ABSTRACT

Background: The societal economic burden of herpes zoster in Sweden is not well described today. This study is a top-down analysis of Swedish registers with the objective to describe the burden of herpes zoster and post-herpetic neuralgia in Sweden during 2011.

Methods: Data for inpatient care; outpatient primary and specialized cares; the prescriptions of drugs, sick leave and the number or diagnostic tests were collected from Swedish national databases. The incidence of the disease was estimated based on the number of prescriptions of antiviral drugs.

Results: The incidence of herpes zoster was estimated to 315 and 577 cases per 100,000 people for patients at all ages and > = 50 years, respectively. Almost 30,000 patients at all ages were diagnosed with herpes zoster and the societal cost to treat these patients, including the cost to treat those patients who later developed post-herpetic neuralgia, added up to nearly 227 MSEK (31.6 M€) which corresponds to 7,600 SEK (€870) per patient. The main contributors to the total cost for the treatment of HZ patients were primary care (43 %); sick leave (28 %); hospitalization (10 %) and specialist care (7 %). Medication was a relatively small contributor with 8.5 MSEK (4 %; 1.0 M€) to the overall costs for patients at all ages. The corresponding total cost including only patients 50 years and older was 168 MSEK (19.2 M€) or 8,200 SEK (€939) per patient.

Conclusions: The current study demonstrates that the burden of herpes zoster is significant in Sweden. The society, the health care payers and the patients potentially have a lot to gain by introducing a vaccination program to patients 50 years and older and as a consequence reduce the economic and clinical burden of herpes zoster and post-herpetic neuralgia.

Show MeSH

Related in: MedlinePlus

Break down of costs for the burden of HZ and PHN in Sweden 2011 for all ages (grey bars) and > =50 years (black bars)
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4493830&req=5

Fig2: Break down of costs for the burden of HZ and PHN in Sweden 2011 for all ages (grey bars) and > =50 years (black bars)

Mentions: The treatment of HZ patients incurs clearly more resource use than the treatment of PHN patients with estimated costs for hospitalization of 23 and 11 MSEK (2.7 and 1.3 M€), primary care of 98 and 1 MSEK (11 and 0.1 M€) and specialist care of 16 and 1 MSEK (1.8 and 0.1 M€), respectively (Fig. 2). The share of hospitalization costs for PHN patients was higher relative to the cost for HZ patients as compared to the corresponding costs for the outpatient cares.


Burden of herpes zoster and post-herpetic neuralgia in Sweden.

Nilsson J, Cassel T, Lindquist L - BMC Infect. Dis. (2015)

Break down of costs for the burden of HZ and PHN in Sweden 2011 for all ages (grey bars) and > =50 years (black bars)
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4493830&req=5

Fig2: Break down of costs for the burden of HZ and PHN in Sweden 2011 for all ages (grey bars) and > =50 years (black bars)
Mentions: The treatment of HZ patients incurs clearly more resource use than the treatment of PHN patients with estimated costs for hospitalization of 23 and 11 MSEK (2.7 and 1.3 M€), primary care of 98 and 1 MSEK (11 and 0.1 M€) and specialist care of 16 and 1 MSEK (1.8 and 0.1 M€), respectively (Fig. 2). The share of hospitalization costs for PHN patients was higher relative to the cost for HZ patients as compared to the corresponding costs for the outpatient cares.

Bottom Line: Medication was a relatively small contributor with 8.5 MSEK (4 %; 1.0 M€) to the overall costs for patients at all ages.The corresponding total cost including only patients 50 years and older was 168 MSEK (19.2 M€) or 8,200 SEK (€939) per patient.The society, the health care payers and the patients potentially have a lot to gain by introducing a vaccination program to patients 50 years and older and as a consequence reduce the economic and clinical burden of herpes zoster and post-herpetic neuralgia.

View Article: PubMed Central - PubMed

Affiliation: Mapi Group, Stockholm, Klarabergsviadukten 90D, SE-111 64, Stockholm, Sweden. Jonas.nilsson@optum.com.

ABSTRACT

Background: The societal economic burden of herpes zoster in Sweden is not well described today. This study is a top-down analysis of Swedish registers with the objective to describe the burden of herpes zoster and post-herpetic neuralgia in Sweden during 2011.

Methods: Data for inpatient care; outpatient primary and specialized cares; the prescriptions of drugs, sick leave and the number or diagnostic tests were collected from Swedish national databases. The incidence of the disease was estimated based on the number of prescriptions of antiviral drugs.

Results: The incidence of herpes zoster was estimated to 315 and 577 cases per 100,000 people for patients at all ages and > = 50 years, respectively. Almost 30,000 patients at all ages were diagnosed with herpes zoster and the societal cost to treat these patients, including the cost to treat those patients who later developed post-herpetic neuralgia, added up to nearly 227 MSEK (31.6 M€) which corresponds to 7,600 SEK (€870) per patient. The main contributors to the total cost for the treatment of HZ patients were primary care (43 %); sick leave (28 %); hospitalization (10 %) and specialist care (7 %). Medication was a relatively small contributor with 8.5 MSEK (4 %; 1.0 M€) to the overall costs for patients at all ages. The corresponding total cost including only patients 50 years and older was 168 MSEK (19.2 M€) or 8,200 SEK (€939) per patient.

Conclusions: The current study demonstrates that the burden of herpes zoster is significant in Sweden. The society, the health care payers and the patients potentially have a lot to gain by introducing a vaccination program to patients 50 years and older and as a consequence reduce the economic and clinical burden of herpes zoster and post-herpetic neuralgia.

Show MeSH
Related in: MedlinePlus